Insys Therapeutics Inc. (NASDAQ:INSY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm presently has a $14.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research’s target price would indicate a potential upside of 3.93% from the […]
